Dow AgroSciences and Schillinger Seed announced Tuesday that the two companies have entered into a licensing, research and development agreement for the commercialization of transgenic commodity soybeans.
Under the agreement, Dow AgroSciences will acquire the Schillinger Seed brand and exclusive right to breed, produce, distribute and sell Schillinger Seed brand transgenic commodity soybeans.
Schillinger will continue to develop and produce proprietary soybean germplasm for Dow AgroSciences to use in breeding and commercial sales. Schillinger will continue to research, develop and market non-genetically modified and specialty soybeans under its recently introduced eMerge Genetics brand.
"This is one more step to expand the soybean genetic platform for Dow AgroSciences," said Jerome Peribere, president and CEO. "Furthermore, this collaboration will help accelerate the development and launch of future traits in soybeans."
John Schillinger, president and CEO of Schillinger Seed, said the agreement was a "win-win" for both companies. "This agreement really allows us to focus on developing and marketing specialty soybeans for the food and feed industry under our eMerge Genetics brand," he said.
Dow AgroSciences will continue to sell Schillinger Seed transgenic soybean seed through Stratton Seed of Stuttgart, Arkansas, in the Southern U.S. Additional terms of the agreement were not disclosed.